Disc Medicine Is Maintained at Outperform by BMO Capital
Disc Medicine Analyst Ratings
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120
Disc Medicine's Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman
Analysts Are Bullish on These Healthcare Stocks: Disc Medicine (IRON), Trevi Therapeutics (TRVI)
Buy Rating for Disc Medicine Driven by Promising Bitopertin Prospects and Strategic Advancements
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine's Strong Financial Health and Promising Clinical Pipeline Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Disc Medicine (IRON) and Roche Holding (OtherRHHBY)
Cantor Fitzgerald Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $132
Disc Medicine Is Maintained at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $132
Jefferies Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111
Disc Medicine Analyst Ratings
Morgan Stanley Initiates Disc Medicine(IRON.US) With Buy Rating, Announces Target Price $85
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)
Cantor Fitzgerald Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $99
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Cuts Target Price to $92
Scotiabank Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $75
Disc Medicine Is Maintained at Sector Outperform by Scotiabank